DiaMedica Therapeutics Inc. (Nasdaq: DMAC), is a clinical-stage biopharmaceutical company that is focused on developing novel treatments where there is significant unmet clinical need or where no current therapies are available, with the focus on acute ischemic stroke and preeclampsia.
For more information please visit www.diamedica.com.
Company Details
- Employees
- 39
- Address
- Two Carlson Parkway,
- Phone
- (763)270-0603
- in****@****ica.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- diamedica.com
- Keywords
- Stroke, Recombinant Protein, Preeclampsia, Biotech.
- HQ
- Minneapolis, MN
Diamedica Therapeutics Inc. Questions
Diamedica Therapeutics Inc.'s helpline number is (763)270-0603
Diamedica Therapeutics Inc.'s website is diamedica.com
Diamedica Therapeutics Inc.'s LinkedIn profile is https://www.linkedin.com/company/diamedica
Diamedica Therapeutics Inc. has
39 employees.
View email and phone details for 39
employees at Diamedica Therapeutics Inc..
Diamedica Therapeutics Inc.'s industry is
Biotechnology Research
Diamedica Therapeutics Inc.'s top competitors are
Apogee Therapeutics,
Checkpoint Therapeutics Inc,
Ionis Pharmaceuticals, Inc.,
Cartesian Therapeutics,
Eikon Therapeutics,
Kanvas Biosciences,
Crinetics Pharmaceuticals,
Celcuity,
N-Power Medicine, Inc.,
Beacon Therapeutics.
Diamedica Therapeutics Inc.'s support email address is info@diamedica.com
Diamedica Therapeutics Inc.'s categories are Biotechnology Research
